Run M1 CRC Challenge Assessment

Your name will be kept confidential to participants and assessor feedback will be forwarded anonymously.
3-digits and starts with a "9"

Patient TC is a 52 year old, previously healthy woman who has presented to the emergency room with a perforated colon adenocarcinoma and evidence of distant metastases.  She has been treated with a right hemicolectomy, and is now being assessed by medical oncology for further management.  The case is being referred for biomarker testing.

DOB: Feb 7 1970 MRN: 12345
REFERENCE RESULTS: MSI-High (MMR-deficient), KRAS G13D
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No

Patient EB is a 42 year old female with a history of metastatic colon adenocarcinoma and a lifetime history of ulcerative colitis, sclerosing cholangitis, and uveitis currently on biologic therapy.  Her treatments to date include a total proctocolectomy, pulmonary metastectomy, followed by systemic therapy with FOLFOX + bevacizumab, and then second-line FOLFIRI.  No previous molecular testing has been performed.  An archival block from her pulmonary metastasis has been referred for molecular testing to help inform the next course of therapy.

DOB: July 2 1980 MRN: 67890
REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Patient JF is a 66 year old man with advanced colorectal carcinoma and peritoneal carcinomatosis.  He has received 6 cycles of FOLFIRI + panitumumab; however his oncologist notes worsening of his ascites and CT scans show definitive disease progression on therapy.  A tumor sample is referred in for molecular testing to inform his next line of therapy.

DOB: March 1, 1956 MRN: 34567
REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No